AbCellera Biologics Inc. (ABCL)
Data as of , from SEC Form 4 filings.
See up to 3 months of ABCL. The 7-day demo opens the 1M and 3M ranges and puts ABCL on your watchlist.
Start 7-day demoLatest ABCL insider trades
Michael R. Hayden - DirectorOpen-market purchase$570K- John S. Montalbano - DirectorOpen-market purchase$110K
About AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. files with the SEC under CIK 0001703057 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
ABCL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 147,200 | $1.55M |
| Bona-fide gift | 1 | 50,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ABCL insider transactions (Form 4)
2119 Form 4 filings on record, the earliest from Nov 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael R. Hayden - Director | Open-market purchase | Common Shares | 53,613 | $10.64 footnote F1 | $570K | |
| ||||||
| John S. Montalbano - Director | Open-market purchase | Common Shares | 10,000 | $11.03 | $110K | |
| Andrew Booth - Officer | Open-market purchase | Common Shares | 37,200 | $10.32 | $384K | |
| Michael R. Hayden - Director | Open-market purchase | Common Shares | 46,387 | $10.37 footnote F1 | $481K | |
| ||||||
| Michael R. Hayden - Director | Gift | Common Shares | 50,000 | $0.00 footnote F1 | - | |
| ||||||
 Lynn Seely - Director | Grant or award | Share option (right to buy) | 152,207 | $0.00 | - | |
| Victor Sandor - Director | Grant or award | Share option (right to buy) | 152,207 | $0.00 | - | |
| Michael R. Hayden - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| Stephen Quake - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| John S. Montalbano - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| Andrew Booth - Officer | Option exercise | Common Shares | 250,000 | $0.19 | $48K | |
| Andrew Booth - Officer | Option exercise | Share option (right to buy) | 250,000 | $0.00 | - | |
| John S. Montalbano - Director | Open-market purchase | Common Shares | 20,000 | $4.77 | $95K | |
| Thermopylae Holdings Ltd. - 10% Owner | Open-market purchase | Common Shares | 38,000 | $3.44 footnote F1 | $131K | |
| ||||||
| Thermopylae Holdings Ltd. - 10% Owner | Open-market purchase | Common Shares | 177,457 | $3.27 footnote F1 | $580K | |
| ||||||
| Andrew Booth - Officer | Open-market purchase | Common Shares | 42,600 | $3.42 | $146K | |
| John S. Montalbano - Director | Open-market purchase | Common Shares | 50,000 | $3.57 | $178K | |
| Michael R. Hayden - Director | Grant or award | Share option (right to buy) | 238,864 | $0.00 | - | |
| Thermopylae Holdings Ltd. - 10% Owner | Gift | Common Shares | 286,000 | $0.00 | - | |
| Carl L. G. Hansen - Officer | Option exercise | Common Shares | 56,125 | $2.70 | $152K | |
| Carl L. G. Hansen - Officer | Option exercise | Share option (right to buy) | 56,125 | $0.00 | - | |
ABCL insider trading FAQ
What is the latest insider trade for ABCL?
AbCellera Biologics Inc. (ABCL) had 5 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for ABCL runs to 19 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ABCL stock?
4 insider purchases of ABCL were filed in the last 90 days, totaling $1.55M.
How many insiders are selling ABCL stock?
No insider sales of ABCL were filed in the last 90 days.
Where can I see ABCL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ABCL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael R. Hayden view on EDGAR
- - John S. Montalbano view on EDGAR
- - Andrew Booth view on EDGAR
- - Michael R. Hayden view on EDGAR
- - Michael R. Hayden view on EDGAR
- - Lynn Seely view on EDGAR
- - Victor Sandor view on EDGAR
- - Michael R. Hayden view on EDGAR
- - Stephen Quake view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ABCL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ABCL with a 7-day demo
- ABCL on your watchlist
- Every ABCL Form 4 filing on record
- Up to 3 months of ABCL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
